Solvotrin Therapeutics Products
Solvotrin Therapeutics’ lead product ST0702 has preclinical proof-of-concept data from in in the clinic.
Solvotrin Therapeutics takes well established therapies and improves them through chemical modification, generating new chemical entities. In some instances this involves creation of hybrids with multiple drug actions. The main breakdown products of these new medicines are well-established and have a known biological profile.
ST0702 is a chemically modified niacin-aspirin prodrug being developed as a “no-flush” niacin, which offers superior efficacy and safety advantages to conventional niacin for treating cholesterol problems. The antidyslipidaemia (cholesterol) market is the second largest therapeutic sub-category of the $170 billion global cardiovascular market, valued at $30 billion annually.
Cancer is a prothrombotic disease whereby patients have increased susceptibility to blood clots and cardiovascular disease. New data on ST0702 demonstrate that it is more effective than aspirin at inhibiting tumour cell induced platelet aggregation. This suggests it would be a better antiplatelet agent than aspirin for patients with cancer.
Financial and regulatory incentives are in place to support the development of drugs for rare diseases (orphan drugs) making this approach commercially attractive for pharmaceutical companies. Orphan indications have been identified for ST0702 in cholesterol and antiplatelet therapy areas.
ST0701 is a form of aspirin that requires bioactivation. Preclinical studies have shown similar antiplatelet efficacy to aspirin, without gastrointestinal toxicity, unlike conventional aspirin.
ST0703 is a “nitro-aspirin” which will offer efficacy and safety advantages over conventional aspirin therapy and over competitor “nitro-aspirin” products.
The bioactivated platform technology is also being developed across a number of other cardio-metabolic and anti-cancer applications, including follow-on niacin prodrugs. Solvotrin Therapeutics’ intellectual property offers a major opportunity with novel, patent-protected medicines at the cutting edge of therapeutics. The company will partner later clinical development of this product with pharmaceutical companies.